BioCentury
DATA GRAPHICS | Product Development

U.S. government spending on Abbott BinaxNOW outstrips other rapid COVID-19 tests: Data Byte

November 26, 2020 12:48 AM UTC

Abbott’s BinaxNOW test has replaced its predecessor as the Trump Administration’s favorite COVID-19 test.

A fact sheet released by HHS Tuesday showed the U.S. federal government has spent $760 million on the antigen test from  Abbott Laboratories (NYSE:ABT). That’s more than triple what it has spent on Abbott’s ID NOW molecular test, which the administration previously touted as a focal point of its COVID-19 response and used to screen visitors to the White House...